General Comments / Chat, page-8673

Not specific to RAC or bisantrene, but as just another retail shareholder..

2 Questions if you don’t mind.

Just in general speaking terms, If i brought a drug off the shelf & started up XYZ biotech Australia. And it turns out theres utility, interest, & clinical need across many continents.

1. Would my smartest commercialisation strategy be targeting a specific indication in a specific country first, to let’s say set the pricing benchmark, before rolling it out to other countries or indications?

2. And let’s say I had 5 possible indications to go after, all each with very different company outcomes: To strike a balance between extracting as much value for my shareholders, where does pricing & size of market of a drug rank when considering a path to commercial outcome?


1. Paths to approval
2. TAM
3. Risk
4. competition
5. patient need
6. Pricing
7. other